ERASErasca, Inc.

HealthcareUSD
$19.16

The financials

Erasca, Inc. by the numbers

Erasca, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$48M−$38Mn/a
Net income−$44M−$34Mn/a
Diluted EPS−$0.14−$0.12n/a

Biotechnology

Ranks #67 of 145 by Smart Score

Compare peers
CELC-0.47%
Celcuity Inc.
EWTX-1.4%
Edgewise Therapeutics, Inc.
TNGX+3.5%
Tango Therapeutics, Inc.
MANE+1.8%
Veradermics, Incorporated
DNTH+0.85%
Dianthus Therapeutics, Inc.
VKTX-2.3%
Viking Therapeutics, Inc.